JCML clinical trials at UCSF

1 research study open to eligible people

Juvenile Myelomonocytic Leukemia (JMML) is a rare blood cancer in children. UCSF is studying the safety of combining trametinib and azacitidine for newly diagnosed patients. This trial helps understand how these drugs work together in treating JMML.

Showing trials for

  • Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

    open to eligible people ages 1 month to 21 years

    This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

    San Francisco, California and other locations

Last updated: